Artiva Biotherapeutics, Inc. ARTV
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -20.88% | -21.40% | -28.29% | -29.23% | -- |
| Total Depreciation and Amortization | 7.01% | 6.59% | 6.83% | 5.56% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.37% | -39.38% | -40.00% | -46.29% | -- |
| Change in Net Operating Assets | 426.88% | 30.32% | -30.46% | -337.51% | -- |
| Cash from Operations | -8.90% | -30.23% | -39.47% | -50.18% | -- |
| Capital Expenditure | 2.78% | -104.23% | -302.96% | -83.69% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 167.73% | 159.66% | 155.08% | 140.21% | -- |
| Cash from Investing | 164.89% | 157.17% | 152.64% | 137.99% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 18.98% | 27.47% | 11.41% | -12.93% | -- |
| Issuance of Common Stock | 79.97% | -99.92% | -99.84% | -99.82% | -- |
| Repurchase of Common Stock | -1,271.79% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -531.34% | 105.68% | 105.57% | 106.65% | -- |
| Cash from Financing | 72.55% | -100.21% | -99.99% | -99.94% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,994.85% | 46.32% | -0.47% | -201.58% | -- |